ClinicalTrials.gg
CompletedNCT05718908FIBROFINUpdated Feb 10, 2023

Study of the Symptomatic Improvement in Patients With Fibromyalgia by Means of a Food Supplement

An observational study in Fibromyalgia, sponsored by Arafarma Group, S.A.. Completed at 1 site in Spain. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-02-10.

Sponsored by Arafarma Group, S.A. · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 151 studies in Fibromyalgia with a site in Spain — 16 open to participants now, 21 under way, none of them phase 3. Fibromyalgia · Spain.

Enrollment
13th of 15
30 · median 90
Started
2022
with 17 others
Observational
15 of 151
2 open now
Registered
111th of 151
by date

Among the 151 studies in Fibromyalgia with a site in Spain, this one is the 13th largest by enrollment of the 15 observational ones that give a count, is one of 18 that started in 2022, is one of 15 observational ones, and was the 111th registered.

Fibromyalgia

1,245 studies on the registry are indexed under Fibromyalgia; 256 are open to participants now.

Browse Fibromyalgia studies →

Open to participants now

16 of the 151 studies in Fibromyalgia with a site in Spain are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 161 Fibromyalgia studies recruiting now, 51 (32%) set no upper age limit and 96 (60%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.

This study: 18 Years and older · female.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 151 studies in Fibromyalgia with a site in Spain, or all of them as a file.
02

Study summary

Fibromyalgia is a syndrome (set of symptoms) of unknown etiology and characterized by diffuse musculoskeletal pain and chronic fatigue. In addition, other symptoms such as cognitive alterations, sleep rhythm disturbances, psychiatric syndromes such as anxiety, depression, etc. Other very characteristic symptoms are hyperalgesia (very low pain threshold) and allodynia (amplified response to painful stimuli).

The treatment of fibromyalgia is symptomatic and the drugs only serve to reduce symptoms in some patients, in addition to the fact that these available treatments (antidepressants, pain signal modulators, rescue analgesics, etc.) have many side effects.

The food supplement which is the object of this study, FibrofixPlus®, is made up of a combination of natural substances.

This is the reason why this observational study aims to improve symptoms caused by fibromyalgia in patients treated with FibrofixPlus®.

Read the detailed description

Patients who meet the fibromyalgia criteria according to the definition of the American College of Rheumatology (ACR) in 1990 and 2010, with a minimum score of 4 on the Visual Analogue Scale (VAS) of Fatigue and Pain and without any treatment (anxiolytics, neuroleptics, antidepressants and/or narcotic analgesics) in a minimum of 4 weeks prior to the beginning of the study, with some exceptions, and who do not meet any of the exclusion criteria will be invited to participate in the study.

There are three study visits which are distributed throughout 8 weeks.

03

Conditions studied

  • Fibromyalgia

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Sampling method
Probability sample

Study population

Women with fibromyalgia in primary care clinic.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women ≥ 18 years.
  • Meet the fibromyalgia criteria according to the definition of the American College of Rheumatology of 1990 and 2010.
  • Minimum score of 4 on the Visual Analogue Scale (VAS) for Fatigue and Pain.
  • Period prior to the start of the study of a minimum of 4 weeks without treatment with anxiolytics, neuroleptics, antidepressants and/or narcotic analgesics. The use of paracetamol up to 2 g/day is allowed, and tramadol 100 mg/8h maximum.

Exclusion criteria

Exclusion Criteria:

  • Current diagnosis of a psychiatric disorder other than major depressive disorder.
  • Pain caused by a traumatic or structural injury.
  • Chronic inflammatory diseases.
  • disease.
  • Use of medications that may interfere with the assessment of pain improvement, including analgesics (with the exception stated in the inclusion criteria), antidepressants, anticonvulsants, or other medication taken to combat fibromyalgia, fatigue or pain.
  • Rehabilitation with therapeutic intent.
  • Intent to apply or current disability application process.
  • Natural therapies (homeotherapy, acupuncture, food, etc.) to improve fibromyalgia.
  • to the active principles or to any of the of the products included in the study.
  • Pregnancy.
  • Breastfeeding.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (actual)
Patient registry
No

Groups and cohorts

  • Fibromyalgia patients

    All patients will be administered with one sachet of food supplement (FibrofixPlus®) per day, for 8 weeks.

    Dietary Supplement: Food supplement

Interventions

  • Dietary supplementFood supplement

    FibrofixPlus® is an authorized food supplement.

06

What researchers measure

Primary outcomes

  1. Symptomatic change of fibromyalgia through the Fibromyalgia Impact Questionnaire (s-FIQ), after taking the FibrofixPlus® food supplement, for 8 weeks.

    To assess the magnitude of the symptomatic improvement by measuring the results to questions of the Fibromyalgia Impact Questionnaire (s-FIQ). This questionnaire scores from 0 to 100, being 0 the best quality of life and functional capacity, and 100 is the worst result.

    Time frame: From Visit 0, and at each visit (Visit 1 or 4 weeks after Visit 0; and Visit 2 or 8 weeks after Visit 0).

Secondary outcomes

  1. Rate of safety episodes.

    All episodes will be recorded, whether considered minor or serious, food supplement-related or not.

    Time frame: Visit 1 to Visit 2, up to 4 weeks.

  2. Change of fatigue symptom through the Visual Analogue Scale (VAS).

    To assess the fatigue symptom by the completion of the Visual Analogue Scale (VAS). The VAS scores from 0 to 10, being 0 the best outcome (without fatigue) and 10 the worst outcome (maximum fatigue).

    Time frame: From Visit 0, and at each visit (Visit 1 or 4 weeks after Visit 0; and Visit 2 or 8 weeks after Visit 0).

  3. Change of fatigue symptom through the Symptom Severity Score (SS Score).

    To assess the fatigue symptom by the completion of the Symptom Severity Score (SS Score). The SS Score has a scoring from 0 to 12, being 0 the best outcome (without fatigue) and 12 the worst outcome (maximum fatigue).

    Time frame: From Visit 0, and at each visit (Visit 1 or 4 weeks after Visit 0; and Visit 2 or 8 weeks after Visit 0).

  4. Change of pain symptom through the Visual Analogue Scale (VAS).

    To assess the pain symptom by the completion of the Visual Analogue Scale (VAS). The VAS scores from 0 to 10, being 0 the best outcome (without fatigue) and 10 the worst outcome (maximum fatigue).

    Time frame: From Visit 0, and at each visit (Visit 1 or 4 weeks after Visit 0; and Visit 2 or 8 weeks after Visit 0).

  5. Change of pain symptom through the Widespread Pain Index (WPI).

    To assess the pain symptom by the completion of the Widespread Pain Index (WPI). The WPI scores from 0 to 19, being the highest result the worst outcome as defined by the number of body areas with pain.

    Time frame: From Visit 0, and at each visit (Visit 1 or 4 weeks after Visit 0; and Visit 2 or 8 weeks after Visit 0).

  6. Change of pain symptom through the Symptom Severity Score (SS Score).

    To assess the pain symptom by the completion of the Symptom Severity Score (SS Score). The SS Score has a scoring from 0 to 12, being 0 the best outcome and 12 the worst outcome.

    Time frame: From Visit 0, and at each visit (Visit 1 or 4 weeks after Visit 0; and Visit 2 or 8 weeks after Visit 0).

  7. Change of the sleep quality through the Pittsburgh Sleep Quality Index (PSQI).

    To assess the sleep quality by the completion of the Pittsburgh Sleep Quality Index (PSQI). The PSQI has a scoring from 0 to 21, being 0 the best outcome with no difficulties to sleep.

    Time frame: From Visit 0, and at each visit (Visit 1 or 4 weeks after Visit 0; and Visit 2 or 8 weeks after Visit 0).

  8. Change of the sleep quality through the Symptom Severity Score (SS Score).

    To assess the sleep quality by the completion of the Symptom Severity Score (SS Score). The SS Score has a scoring from 0 to 12, being 0 the best outcome and 12 the worst outcome.

    Time frame: From Visit 0, and at each visit (Visit 1 or 4 weeks after Visit 0; and Visit 2 or 8 weeks after Visit 0).

  9. Change on the functional impairment through the questionnaire Clinical Global Impressions (CGI).

    To assess the functional impairment by the completion of the Clinical Global Impressions (CGI). The CGI has a scoring from 0 to 7, being 0 "not assessed" and 1 "normal or not ill" and 7 "extremely ill".

    Time frame: From Visit 0, and at each visit (Visit 1 or 4 weeks after Visit 0; and Visit 2 or 8 weeks after Visit 0).

  10. Change on the functional impairment through the questionnaire Short Form-36 Questionnaire (SF-36).

    To assess the functional impairment by the completion of the Short Form-36 Questionnaire (SF-36). The SF-36 has several questions so when the scoring is higher, better is the health status. The global score is between 0 and 100, being 0 the worst and 100 the best health status.

    Time frame: At Visit 0 and at Visit 2, or 8 weeks after Visit 0.

  11. Change on the quality of life through the questionnaire Clinical Global Impressions (CGI).

    To assess the quality of life by the completion of the questionnaire CGI. The CGI has a scoring from 0 to 7, being 0 "not assessed" and 1 "normal or not ill" and 7 "extremely ill".

    Time frame: From Visit 0, and at each visit (Visit 1 or 4 weeks after Visit 0; and Visit 2 or 8 weeks after Visit 0).

  12. Change on the quality of life through the questionnaire Hospital Anxiety and Depression Scale (HADS).

    To assess the quality of life by the completion of the HADS. The HADS has a maximum score of 21, which indicates a severe or worse status.

    Time frame: At Visit 0 and at Visit 2, or 8 weeks after Visit 0.

  13. Change on the quality of life through the questionnaire Short Form-36.

    To assess the quality of life by the completion of the Short Form-36 Questionnaire (SF-36). The SF-36 has several questions so when the scoring is higher, better is the health status. The global score is between 0 and 100, being 0 the worst and 100 the best health status.

    Time frame: At Visit 0 and at Visit 2, or 8 weeks after Visit 0.

07

Study locations

1 site
  • Hospital Clínic Barcelona
    Barcelona, 08036, Spain
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2022 to primary completion in Sep 2022, 5 months.

Of 88 observational studies under Fibromyalgia, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 91. This study's 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 28, 2022
First posted
Feb 8, 2023
StartActual
Mar 9, 2022
Primary completionActual
Sep 6, 2022
CompletionActual
Nov 8, 2022
Last update
Feb 10, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05718908
Lead sponsor
Arafarma Group, S.A.
Responsible party
Sponsor
First posted
Feb 8, 2023
Start date
Mar 9, 2022
Primary completion
Sep 6, 2022
Completion
Nov 8, 2022
Last update
Feb 10, 2023

Study contacts

Rodríguez Araya, Dr
principal investigator · Hospital Clinic of Barcelona

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion